About Blaze Bioscience
Blaze Bioscience is a company based in Seattle (United States) founded in 2010. It operates as a HealthTech. Blaze Bioscience has raised $123.7 million across 12 funding rounds. The company has 27 employees as of December 31, 2022. Blaze Bioscience offers products and services including Tumor Paint, CANVAS Imaging System, and Tozuleristide. Blaze Bioscience operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seattle, United States
- Employees 27 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Blaze Bioscience, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$123.7 M (USD)
in 12 rounds
-
Latest Funding Round
$8.06 M (USD), Series D
Feb 15, 2024
-
Investors
Not available
-
Employee Count
27
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blaze Bioscience
Blaze Bioscience offers a comprehensive portfolio of products and services, including Tumor Paint, CANVAS Imaging System, and Tozuleristide.
Technology is used for cancer detection and removal.
System is designed to enhance cancer treatment imaging.
Drug is developed for cancer surgery imaging applications.
People of Blaze Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Blaze Bioscience
Blaze Bioscience has successfully raised a total of $123.7M across 12 strategic funding rounds. The most recent funding activity was a Series D round of $8.06 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Blaze Bioscience
Investment portfolio details for Blaze Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Blaze Bioscience
Detailed financials for Blaze Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Blaze Bioscience Comparisons
Peer comparison for Blaze Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Blaze Bioscience
Blaze Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Blaze Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Blaze Bioscience
Complete news archive for Blaze Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blaze Bioscience
Blaze Bioscience was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Blaze Bioscience is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Blaze Bioscience is a funded company, having raised a total of $123.7M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Blaze Bioscience is 27.
Blaze Bioscience, Inc. is dedicated to enhancing the lives of cancer patients through innovative biotechnology solutions. The company is engaged in the development of Tumor Paint technology, including the CANVAS imaging system, to improve the detection, removal, and treatment of cancers. Solutions are aimed at making cancer management more sensitive, reliable, and accessible. The focus is placed on applications in cancer surgery, high-risk surveillance, and screening through collaborations and partnerships.
Blaze Bioscience's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Blaze Bioscience offers Tumor Paint, CANVAS Imaging System, and Tozuleristide.